Omeros (OMER) said Wednesday the results of a study evaluating the efficacy and safety of its investigational drug narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy were posted online in the Journal of Clinical Oncology.
The study's conclusion said treatment with narsoplimab was safe and "resulted in clinical response and favorable overall survival."
Omeros shares were down 7% on Wednesday morning.
Price: 4.41, Change: -0.29, Percent Change: -6.17